No, not in terms of the application process, but there are definitely some ongoing small-scale clinical trials by some of the licensed producers. It's not nearly to the degree that we would like to see it. We'd also like to see the $25 million invested in CIHR so they can grant it out, so that it's unbiased research and not necessarily sponsored by drug companies.
Really, it does come back to the research. Again, the patentability, as well as the wide range of indications, means that there's a lot of research to be done. It's expensive clinical research. The Arthritis Society held a forum a couple of years ago, brought all the researchers together, and created a report that set out a list of priorities. Now we have the priorities. We know what we need to study. We just need the funding to enable us to do that.